The effects of combined therapy of myo-inositol and D-chiro inositol in reduction of the individual components of metabolic syndrome in overweight PCOS patients compared to myo-inositol supplementation alone: a prospective randomised controlled trial

Abstract

Background: Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorder affecting five to ten percent women of reproductive age group. Variability of signs and symptoms along with metabolic syndrome as one of the long term complications make it worthy of early diagnosis and treatment. Medical management of PCOS is aimed at the treatment of metabolic derangements, anovulation, hirsutism, and menstrual irregularities.Methods: 140 patients, using inclusion and exclusion criteria, were selected and randomly divided into two groups (seventy in each) and age, BMI, waist hip ratio, blood pressure (systolic, diastolic), serum fasting insulin, fasting blood sugar, total cholesterol, HDL, LDL, triglycerides were measured. Study group were given {Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg)} (MI+DCI) twice daily and the control group were given Myo-inositol (1 gm) (MI) twice daily for six months. Same variables were measured at the end of three and six months and compared with repeated measurement ANOVA using SPSS (version 20).Results: Comparison between these two groups before study was non-contributory. Combined drug therapy has provided statistically significant decrease in BMI, W:H ratio, Diastolic BP, Fasting blood sugar at the end of both 3rd and 6th month but in case of LDL it was at the end of 3 months. Combined drug therapy also increased the HDL level significantly in both the occasions.Conclusions: Combined medical therapy by (MI+DCI) is very much helpful in reducing the metabolic complications of PCOS without any major side effects.

Health-Promoting Properties of Selected Cyclitols for Metabolic Syndrome and Diabetes

“…In an animal model of diabetes, DP has been described as an anti-diabetic drug, with an insulin-like effect and the ability to enhance insulin activity by translocation of the GLUT in the mice skeletal muscles [52,63]. In patients with T2DM, treatment with pinitol improved glycemic control, decreased the level of adipocytokines, and decreased metabolic parameters associated with the risk of cardiovascular diseases [62]. In the cardiovascular system, DP was able to prevent diabetic-induced endothelial dysfunctions in the mesenteric artery.…”

“…Therefore, the choice of the initial dose of such drugs for research, experimentation, or clinical trials is a problem. It should be emphasized that widespread dose scaling based solely on body weight (mg/kg) is not an appropriate approach, because the biochemical and functional systems, particularly in pharmacokinetics, differ in different species [61,62].…”

A comprehensive overview of role of combined myoinositol and D-chiroinositol (40:1 ratio) therapy in the management of PCOS

“…The available studies of MI+DCI combination are summarized in below. [45][46][47][50][51][52] (Table 1).…”

“…[45][46][47][50][51][52] Compared to the MI group, the decrement of total testosterone and the increment of the serum sex hormone binding globulin were more relevant in MI+DCI group both at 3 month and at 6month. In both groups there was a striking improvement of the ovulation function.…”

Amperometric determination of myo-inositol by using a glassy carbon electrode modified with molecularly imprinted polypyrrole, reduced graphene oxide and nickel nanoparticles

“…Myo-inositol is a cyclic polyalcohol found in animals, plants, seeds, fungi and some bacteria [1]. Its benefits to human health include treatment and prevention of anxiety [2,3], dietary supplement for the promotion of female fertility [4], besides playing an important role in monitoring the treatment of cardiovascular diseases [5], Alzheimer [6], diabetes and renal disease [7].…”